A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder

In brief

The objectives of this time-to-event study were to assess the efficacy and safety of eculizumab as compared with placebo in participants with neuromyelitis optica spectrum disorder (NMOSD) who were anti-aquaporin-4 (AQP4) antibody-positive.

Key facts

Study ID
NCT01892345
Run by
Alexion Pharmaceuticals, Inc.
People needed
143
Starts
2014-04-11
Expected to finish
2018-07-17
Last updated by the study team
2019-06-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.